All Stories

  1. Counterpoint: Twice-Weekly Hemodialysis Should Be an Approach of Last Resort Even in Times of Dialysis Unit Stress
  2. Advancing American Kidney Health
  3. CJASN and Disclosure of Conflicts of Interest
  4. CJASN: What’s Behind and What’s Ahead
  5. Perspectives on Funding Initiatives in Clinical Research in Kidney Disease in the United States
  6. Sex Differences in Hospitalizations with Maintenance Hemodialysis
  7. Introduction to 30 Years: Lessons Learned in Dialysis
  8. Initial Session Duration and Mortality Among Incident Hemodialysis Patients
  9. CJASN : Turning the Page
  10. Metabolic Effects of Peritoneal Dialysis
  11. Abdominal Catastrophes, Peritoneal Eosinophilia, and Other Unusual Events in Peritoneal Dialysis
  12. Components of A Successful Peritoneal Dialysis Program
  13. Concurrence of Serum Creatinine and Albumin With Lower Risk for Death in Twice-Weekly Hemodialysis Patients
  14. Changes in the worldwide epidemiology of peritoneal dialysis
  15. Extended-hours hemodialysis is associated with lower mortality risk in patients with end-stage renal disease
  16. The Current State of Hemodialysis Access and Dialysis Access Initiatives in the United States
  17. Treatment frequency and mortality among incident hemodialysis patients in the United States comparing incremental with standard and more frequent dialysis
  18. Serum amyloid a and risk of death and end-stage renal disease in diabetic kidney disease
  19. Thyroid Functional Disease and Mortality in a National Peritoneal Dialysis Cohort
  20. Vascular Access for Hemodialysis and Value-Based Purchasing for ESRD
  21. Serum Magnesium Levels and Hospitalization and Mortality in Incident Peritoneal Dialysis Patients: A Cohort Study
  22. Racial Differences in Survival of Incident Home Hemodialysis and Kidney Transplant Patients
  23. Mean platelet volume and mortality risk in a national incident hemodialysis cohort
  24. Survival of Elderly Adults Undergoing Incident Home Hemodialysis and Kidney Transplantation
  25. Predictive Score for Posttransplantation Outcomes
  26. Serum sodium and mortality in a national peritoneal dialysis cohort
  27. Hidden Hypercalcemia and Mortality Risk in Incident Hemodialysis Patients
  28. Patient and Other Stakeholder Engagement in Patient-Centered Outcomes Research Institute Funded Studies of Patients with Kidney Diseases
  29. New-Onset Diabetes in Peritoneal Dialysis Patients – Which Predictors Really Matter?
  30. The Evolving Ethics of Dialysis in the United States: A Principlist Bioethics Approach
  31. Vascular access in home dialysis
  32. Urine matrix metalloproteinase-7 and risk of kidney disease progression and mortality in type 2 diabetes
  33. Peritoneal Equilibration Test and Patient Outcomes
  34. Peritoneal dialysis
  35. The intact nephron hypothesis in reverse: an argument to support incremental dialysis
  36. Association of plasma F2-isoprostanes and isofurans concentrations with erythropoiesis-stimulating agent resistance in maintenance hemodialysis patients
  37. FP555SERUM SODIUM AND MORTALITY IN A US PERITONEAL DIALYSIS COHORT
  38. American Society of Nephrology Quiz and Questionnaire 2014: RRT
  39. Predictors of treatment with dialysis modalities in observational studies for comparative effectiveness research
  40. A Pilot Randomized Crossover Trial Assessing the Safety and Short-Term Effects of Pomegranate Supplementation in Hemodialysis Patients
  41. Changes in symptom burden and physical performance with initiation of dialysis in patients with chronic kidney disease
  42. Surviving the First Year of Peritoneal Dialysis: Enduring Hard Times
  43. The changing landscape of home dialysis in the United States
  44. Effect of Medicare Dialysis Payment Reform on Use of Erythropoiesis Stimulating Agents
  45. Alkaline phosphatase: Better than PTH as a marker of cardiovascular and bone disease?
  46. The Kidney Research National Dialogue: Gearing Up to Move Forward
  47. Pharmacokinetic Assessment in Patients Receiving Continuous RRT: Perspectives from the Kidney Health Initiative
  48. A Palliative Approach to Dialysis Care: A Patient-Centered Transition to the End of Life
  49. Insulin resistance in chronic kidney disease: a step closer to effective evaluation and treatment
  50. Diagnostic Testing for Peritonitis in Patients Undergoing Peritoneal Dialysis
  51. Comparative Outcomes Between Continuous Ambulatory and Automated Peritoneal Dialysis: A Narrative Review
  52. American Society of Nephrology Quiz and Questionnaire 2013: RRT
  53. Effect of Age and Dialysis Vintage on Obesity Paradox in Long-term Hemodialysis Patients
  54. Is Early Initiation of Dialysis Harmful?
  55. Educational programs improve the preparation for dialysis and survival of patients with chronic kidney disease
  56. Dialysis Therapies: A National Dialogue
  57. An Estimation of the Prevalence and Progression of Chronic Kidney Disease in a Rural Diabetic Cambodian Population
  58. Outcomes of Kidney Replacement Therapies
  59. Adverse effects of systemic glucose absorption with peritoneal dialysis
  60. Initiation of Dialysis Should be Timely: Neither Early Nor Late
  61. Medication Reconciliation and Therapy Management in Dialysis-Dependent Patients: Need for a Systematic Approach
  62. Dancing around Elephants
  63. Nutritional Issues in Peritoneal Dialysis Patients: How Do They Differ From That of Patients Undergoing Hemodialysis?
  64. American Society of Nephrology Quiz and Questionnaire 2012: Renal Replacement Therapy
  65. Is Dorothy Correct? The Role of Patient Education in Promoting Home Dialysis
  66. Comparing Mortality of Peritoneal and Hemodialysis Patients in the First 2 Years of Dialysis Therapy: A Marginal Structural Model Analysis
  67. Dialysis in 2012: Could longer and more frequent haemodialysis improve outcomes?
  68. Nutrition and Anemia in End-stage Renal Disease
  69. Causes of Protein-Energy Wasting in Chronic Kidney Disease
  70. Nutritional Management of End-Stage Renal Disease Patients Treated with Peritoneal Dialysis
  71. Overview of Peritoneal Dialysis
  72. Using Hemoglobin A1c to Derive Mean Blood Glucose in Peritoneal Dialysis Patients
  73. Dialysis Modality and Correction of Uremic Metabolic Acidosis: Relationship with All-Cause and Cause-Specific Mortality
  74. Change in ankle-brachial index over time and mortality in diabetics with proteinuria
  75. How to Overcome Barriers and Establish a Successful Home HD Program
  76. Peritoneal Dialysis-Associated Peritonitis with Simultaneous Exit-Site Infection
  77. Searching for new care models for chronic kidney disease
  78. Serum Potassium And Cause-Specific Mortality In A Large Contemporary Peritoneal Dialysis Cohort
  79. Serum Bicarbonate And Survival In Peritoneal Dialysis (Pd): Comparison With Hemodialysis (Hd)
  80. Fosrenol for Enhancing Dietary Protein Intake in Hypoalbuminemic Dialysis Patients (FrEDI) Study
  81. Serum Potassium and Cause-Specific Mortality in a Large Peritoneal Dialysis Cohort
  82. Comparing Mandated Health Care Reforms: The Affordable Care Act, Accountable Care Organizations, and the Medicare ESRD Program
  83. Considerations in the optimal preparation of patients for dialysis
  84. Expanding Access to Peritoneal Dialysis for Incident Dialysis Patients
  85. Cardiovascular disease in chronic kidney disease
  86. Mortality Associated with Dose Response of Erythropoiesis-Stimulating Agents in Hemodialysis versus Peritoneal Dialysis Patients
  87. Comparing Outcomes of Hemodialysis and Peritoneal Dialysis Patients: Consider the Pitfalls
  88. Prospective Safety Study of Bardoxolone Methyl in Patients with Type 2 Diabetes Mellitus, End-Stage Renal Disease and Peritoneal Dialysis
  89. Insights into nephrologist training, clinical practice, and dialysis choice
  90. Dialysis Modality and Outcomes in Kidney Transplant Recipients
  91. Choice of dialysis modality
  92. Racial and Ethnic Differences in the Association of Body Mass Index and Survival in Maintenance Hemodialysis Patients
  93. Serum Albumin as a Predictor of Mortality in Peritoneal Dialysis: Comparisons With Hemodialysis
  94. Bridging the Care Gap Around Dialysis Initiation: Is CKD Education Part of the Solution?
  95. Diets and enteral supplements for improving outcomes in chronic kidney disease
  96. Implications of a Nephrology Workforce Shortage for Dialysis Patient Care
  97. An Update on the Comparisons of Mortality Outcomes of Hemodialysis and Peritoneal Dialysis Patients
  98. Similar Outcomes With Hemodialysis and Peritoneal Dialysis in Patients With End-Stage Renal Disease
  99. Vitamin D and Cardiovascular Disease: Potential Role in Health Disparities
  100. Novel Equations to Estimate Lean Body Mass in Maintenance Hemodialysis Patients
  101. Peritoneal dialysis: an underutilized modality
  102. The Obesity Paradox and Mortality Associated With Surrogates of Body Size and Muscle Mass in Patients Receiving Hemodialysis
  103. Phosphorus and coronarycalcification in predialysis patients
  104. What Should Define Optimal Correction of Metabolic Acidosis in Chronic Kidney Disease?
  105. Impact of race on hyperparathyroidism, mineral disarrays, administered vitamin D mimetic, and survival in hemodialysis patients
  106. Measuring Vascular Calcification Clinical Practice
  107. Coronary artery calcification and mortality in diabetic patients with proteinuria
  108. 82: Hemoglobin A1c and 5-Year Survival in 2,798 Chronic Peritoneal Dialysis Patients With Diabetes Mellitus
  109. 131: Comparison of Mortality of Incident Peritoneal Dialysis (Pd) and Hemodialysis (Hd) Patients by Age and Diabetes in a National Cohort
  110. The Utilization and Outcome of Peritoneal Dialysis
  111. Association of Cumulatively Low or High Serum Calcium Levels with Mortality in Long-Term Hemodialysis Patients
  112. Association of Hemodialysis Treatment Time and Dose With Mortality and the Role of Race and Sex
  113. Chronic kidney disease, hypovitaminosis D, and mortality in the United States
  114. The outcomes of continuous ambulatory and automated peritoneal dialysis are similar
  115. Vascular Calcification in Chronic Kidney Disease
  116. Correction of Metabolic Acidosis to Ameliorate Wasting in Chronic Kidney Disease: Goals and Strategies
  117. Nodular glomerulosclerosis in a patient with metabolic syndrome without diabetes
  118. Racial Differences in Mortality and ESRD
  119. RESPONSE LETTER TO DRS. SUTIN AND ROUGAS
  120. Abdominal Catastrophes, Peritoneal Eosinophilia, and Other Unusual Events in Peritoneal Dialysis
  121. Cardiovascular Implications of Chronic Kidney Disease in Older Adults
  122. Poor correlation between coronary artery calcification and obstructive coronary artery disease in an end-stage renal disease patient
  123. “Healthy” Initiation of Chronic Dialysis: Current Research Needs
  124. Quality Indicators for the Care of Hypertension in Vulnerable Elders
  125. Prevalence of Cardiovascular Risk Factors and the Serum Levels of 25-Hydroxyvitamin D in the United States
  126. Does in vitro fluoroquinolone resistance predict clinical failure in urinary tract infections?
  127. 144
  128. VASCULAR CALCIFICATION IN PATIENTS WITH KIDNEY DISEASE: Vascular Calcification and Disordered Mineral Metabolism in Dialysis Patients
  129. Strong association of carotid plaques with mortality and cardiovascular morbidity in hemodialysis patients
  130. Disordered Mineral Metabolism and Vascular Calcification in Nondialyzed Chronic Kidney Disease Patients
  131. Progression of coronary artery calcification in diabetics with and without chronic kidney disease
  132. Patient education and access of ESRD patients to renal replacement therapies beyond in-center hemodialysis
  133. Risks of chronic metabolic acidosis in patients with chronic kidney disease
  134. Coronary artery calcification in nondialyzed patients with chronic kidney diseases
  135. Diabetes and progression of coronary calcium under the influence of statin therapy
  136. Serum fetuin-A in nondialyzed patients with diabetic nephropathy: Relationship with coronary artery calcification
  137. POOR NUTRITIONAL STATUS AND INFLAMMATION: Metabolic Acidosis and Malnutrition-Inflammation Complex Syndrome in Chronic Renal Failure
  138. Determinants of coronary artery calcification in diabetics with and without nephropathy
  139. Differential management of cardiovascular disease in ESRD by nephrologists and cardiologists
  140. Age-related decline in serum parathyroid hormone in maintenance hemodialysis patients is independent of inflammation and dietary nutrient intake
  141. Metabolic acidosis in maintenance dialysis patients: Clinical considerations
  142. Protein and energy nutrition among adult patients treated with chronic peritoneal dialysis
  143. Coronary artery, aortic wall, and valvular calcification in nondialyzed individuals with type 2 diabetes and renal disease
  144. Diabetes and progression of coronary calcium score using electron beam tomography
  145. Improvement of nutritional status after initiation of maintenance hemodialysis
  146. An analysis of dialysis training in the United States and Canada
  147. Peritoneal Ultrafiltration for Chronic Congestive Heart Failure: Rationale, Evidence and Future
  148. Observations with Regard to the National Kidney Foundation K/DOQI Clinical Practice Guidelines Concerning Serum Transthyretin in Chronic Renal Failure
  149. NUTRITIONAL MANAGEMENT OF MAINTENANCE DIALYSIS PATIENTS: Why Aren't We Doing Better?
  150. Peritoneal Dialysis Should be the First Choice of Initial Renal Replacement Therapy for More Patients With End-Stage Renal Disease
  151. Treatment of advanced renal failure: Low-protein diets or timely initiation of dialysis?
  152. Another Call for Timely Initiation of Dialysis
  153. Low Protein Diets Are Not Needed in Chronic Renal Failure
  154. Longitudinal Evaluation of a Renal Kt/VUrea of 2.0 as a Threshold for Initiation of Dialysis
  155. Evidence That Urea Is a Better Surrogate Marker of Uremic Toxicity Than Creatinine
  156. Hypokalemic metabolic alkalosis with hypomagnesuric hypermagnesemia and severe hypocalciuria: A new syndrome?